OSELTAMIVIR PHOSPHATE

N/A

Manufactured by Genentech, Inc.

43,488 FDA adverse event reports analyzed

Last updated: 2026-04-14

About OSELTAMIVIR PHOSPHATE

OSELTAMIVIR PHOSPHATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Genentech, Inc.. The most commonly reported adverse reactions for OSELTAMIVIR PHOSPHATE include OFF LABEL USE, VOMITING, NO ADVERSE EVENT, NAUSEA, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for OSELTAMIVIR PHOSPHATE.

Top Adverse Reactions

OFF LABEL USE2,050 reports
VOMITING2,022 reports
NO ADVERSE EVENT1,582 reports
NAUSEA1,523 reports
DRUG INEFFECTIVE1,216 reports
INFLUENZA1,140 reports
DIARRHOEA1,012 reports
DYSPNOEA966 reports
ABNORMAL BEHAVIOUR963 reports
HEADACHE900 reports
PYREXIA897 reports
PNEUMONIA895 reports
HALLUCINATION870 reports
RASH725 reports
COUGH643 reports
DRUG EXPOSURE DURING PREGNANCY643 reports
DEATH585 reports
ABDOMINAL PAIN584 reports
PAIN556 reports
DIZZINESS522 reports
FATIGUE505 reports
MALAISE499 reports
ANXIETY485 reports
CONDITION AGGRAVATED451 reports
URTICARIA450 reports
INSOMNIA447 reports
ACUTE KIDNEY INJURY446 reports
CONFUSIONAL STATE441 reports
HYPERSENSITIVITY417 reports
SEPSIS393 reports
ASTHENIA389 reports
CHRONIC KIDNEY DISEASE382 reports
DRUG INTOLERANCE378 reports
DRUG HYPERSENSITIVITY372 reports
NORMAL NEWBORN369 reports
CONSTIPATION367 reports
RENAL FAILURE367 reports
ASTHMA364 reports
PRODUCT USE IN UNAPPROVED INDICATION359 reports
PRURITUS359 reports
PREGNANCY356 reports
DELIRIUM353 reports
MATERNAL EXPOSURE DURING PREGNANCY334 reports
ABDOMINAL PAIN UPPER330 reports
OVERDOSE326 reports
CHEST DISCOMFORT310 reports
RESPIRATORY FAILURE309 reports
SOMNOLENCE306 reports
WHEEZING299 reports
SWELLING FACE294 reports
NEUTROPENIA291 reports
ABDOMINAL DISTENSION290 reports
GENERAL PHYSICAL HEALTH DETERIORATION288 reports
DECREASED APPETITE287 reports
FEELING ABNORMAL287 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME286 reports
ANAEMIA282 reports
RHINORRHOEA280 reports
HYPONATRAEMIA276 reports
ARTHRALGIA273 reports
DRUG INTERACTION271 reports
FOETAL EXPOSURE DURING PREGNANCY271 reports
DEPRESSION268 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION263 reports
FALL263 reports
LOSS OF CONSCIOUSNESS242 reports
NASAL CONGESTION241 reports
SWOLLEN TONGUE241 reports
STRESS239 reports
TREMOR238 reports
DYSPHONIA237 reports
BREATH SOUNDS ABNORMAL233 reports
ANGIOEDEMA231 reports
BACK PAIN231 reports
SLEEP DISORDER231 reports
FULL BLOOD COUNT ABNORMAL229 reports
CONVULSION226 reports
ASCITES225 reports
BLOOD POTASSIUM DECREASED223 reports
PAIN IN EXTREMITY220 reports
SNEEZING218 reports
AGITATION214 reports
PULMONARY EMBOLISM213 reports
CHEST X RAY ABNORMAL210 reports
APPENDICITIS208 reports
CHEST PAIN208 reports
DEHYDRATION208 reports
CARDIOGENIC SHOCK207 reports
END STAGE RENAL DISEASE206 reports
THROMBOCYTOPENIA206 reports
BLOOD LACTIC ACID INCREASED204 reports
EAR PRURITUS202 reports
VENTRICULAR FIBRILLATION199 reports
INCORRECT DOSE ADMINISTERED198 reports
LACRIMATION INCREASED197 reports
INTENTIONAL PRODUCT MISUSE196 reports
WEIGHT DECREASED196 reports
APPENDICOLITH195 reports
SWELLING195 reports
EYE PRURITUS194 reports

Report Outcomes

Out of 23,757 classified reports for OSELTAMIVIR PHOSPHATE:

Serious 65.3%Non-Serious 34.7%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female11,726 (55.9%)
Male9,146 (43.6%)
Unknown108 (0.5%)

Reports by Age

Age 80377 reports
Age 6360 reports
Age 5355 reports
Age 8330 reports
Age 7326 reports
Age 60321 reports
Age 4314 reports
Age 41294 reports
Age 61279 reports
Age 3262 reports
Age 2239 reports
Age 9239 reports
Age 10233 reports
Age 40227 reports
Age 12226 reports
Age 11225 reports
Age 35197 reports
Age 50195 reports
Age 66195 reports
Age 13194 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with OSELTAMIVIR PHOSPHATE?

This profile reflects 43,488 FDA FAERS reports that mention OSELTAMIVIR PHOSPHATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for OSELTAMIVIR PHOSPHATE?

Frequently reported terms in FAERS include OFF LABEL USE, VOMITING, NO ADVERSE EVENT, NAUSEA, DRUG INEFFECTIVE, INFLUENZA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures OSELTAMIVIR PHOSPHATE?

Labeling and FAERS entries often list Genentech, Inc. in connection with OSELTAMIVIR PHOSPHATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.